basimglurant   Click here for help

GtoPdb Ligand ID: 9309

Synonyms: compound 2 [PMID: 25565255] | RG-7090 | RO-4917523 | Ro4917523
Compound class: Synthetic organic
Comment: Basimglurant (RO4917523) is a negative allosteric modulator (NAM) of the glutamate metabotropic receptor 5 (mGlu5) GPCR [1], and is a clinical candidate in development for the treatment of psychiatric diseases. Structurally, basimglurant and CTEP [2] are analogues. CTEP has a notably longer half-life in rodents (49 hours) than basimglurant (~10 hours), so is better suited for rodent studies requiring chronic exposure/treatment.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 2
Hydrogen bond donors 0
Rotatable bonds 1
Topological polar surface area 30.19
Molecular weight 325.08
XLogP 4.85
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES Fc1ccc(cc1)n1c(C)nc(c1C)C#Cc1ccnc(c1)Cl
Isomeric SMILES Fc1ccc(cc1)n1c(C)nc(c1C)C#Cc1ccnc(c1)Cl
InChI InChI=1S/C18H13ClFN3/c1-12-17(8-3-14-9-10-21-18(19)11-14)22-13(2)23(12)16-6-4-15(20)5-7-16/h4-7,9-11H,1-2H3
InChI Key UPZWINBEAHDTLA-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Basimglurant (RO4917523) has completed Phase 2 clinical trials for major depressive disorder and fragile X syndrome (see NCT01437657 and NCT01015430 as examples)
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Fragile X syndrome (FXS): Increased mGlu5 receptor activity is believed to underlie disease-related phenotypes in FXS, with symptoms improved by pharmacological or genetic inhibition of mGlu5 receptor activity. mGlu5 NAMs such as basimglurant are being evaluated for their clinical efficacy in improving FXS pathophysiology.
Depression:Evidence suggests that the pathophysiology of depression can be the result of glutamatergic system dysfunction, with predictions that pharmacological modulation of glutamatergic neurotransmission may deliver antidepressant effects. Initial preclinical studies focussed on mGlu5 antagonists (e.g. MPEP and MTEP), and has more recently shifted towards investigating mGlu5 NAMs.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01015430 A Study With RO4917523 in Patients With Fragile X Syndrome Phase 2 Interventional Hoffmann-La Roche
NCT01437657 MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy Phase 2 Interventional Hoffmann-La Roche